Literature DB >> 6660847

Amoxicillin combined with clavulanic acid for the treatment of soft tissue infections in children.

G R Fleisher, C M Wilmott, J M Campos.   

Abstract

We compared responses to amoxicillin combined with clavulanic acid (ACA) with a cefaclor regimen in children with skin and soft tissue infections (impetigo and cellulitis) due to Staphylococcus aureus, Streptococcus pyogenes, and Haemophilus species. All isolates from the 41 patients we were able to evaluate were susceptible to ACA by disk susceptibility testing at the onset of treatment. The 21 children receiving ACA and 18 (90%) of 20 taking cefaclor responded to therapy. Clinical cure was achieved in 18 (86%) of 21 and 18 (90%) of 20 in the two groups, respectively. Bacteriological failure occurred in 2 (10%) patients in the cefaclor group and none in the group receiving ACA; however, there were 2 (9%) relapses and 1 (5%) reinfection among the 21 children taking ACA. Adverse effects, although mild, occurred more commonly (9 of 21 versus 1 of 20; P = 0.005) with ACA than with cefaclor.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6660847      PMCID: PMC185924          DOI: 10.1128/AAC.24.5.679

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  10 in total

1.  Clavulanic acid: a beta-lactamase-inhiting beta-lactam from Streptomyces clavuligerus.

Authors:  C Reading; M Cole
Journal:  Antimicrob Agents Chemother       Date:  1977-05       Impact factor: 5.191

2.  Effect of clavulanic acid on the minimum inhibitory concentration of benzylpenicillin, ampicillin, carbenicillin, or cephalothin against clinical isolates resistant to beta-lactam antibiotics.

Authors:  L Dumon; P Adriaens; J Anné; H Eyssen
Journal:  Antimicrob Agents Chemother       Date:  1979-02       Impact factor: 5.191

3.  Effect of clavulanic acid and amoxycillin formulation against beta-lactamase producing Gram-negative bacteria in urinary tract infections.

Authors:  F W Goldstein; M D Kitzis; J F Acar
Journal:  J Antimicrob Chemother       Date:  1979-11       Impact factor: 5.790

4.  Clavulanic acid and amoxycillin: a clinical, bacteriological, and pharmacological study.

Authors:  A P Ball; A M Geddes; P G Davey; I D Farrell; G R Brookes
Journal:  Lancet       Date:  1980-03-22       Impact factor: 79.321

5.  Cellulitis: bacterial etiology, clinical features, and laboratory findings.

Authors:  G Fleisher; S Ludwig; J Campos
Journal:  J Pediatr       Date:  1980-10       Impact factor: 4.406

6.  Bronchopulmonary infection due to beta-lactamase-producing Branhamella catarrhalis treated with amoxycillin/clavulanic-acid.

Authors:  G Ninane; J Joly; M Kraytman; P Piot
Journal:  Lancet       Date:  1978-07-29       Impact factor: 79.321

7.  Clavulanic acid, a novel inhibitor of beta-lactamases.

Authors:  H C Neu; K P Fu
Journal:  Antimicrob Agents Chemother       Date:  1978-11       Impact factor: 5.191

8.  Pharmacokinetics of potassium clavulanate in combination with amoxicillin in pediatric patients.

Authors:  J D Nelson; H Kusmiesz; S Shelton
Journal:  Antimicrob Agents Chemother       Date:  1982-04       Impact factor: 5.191

9.  A combination of amoxicillin and clavulanic acid in the treatment of respiratory tract infections caused by amoxicillin-resistant haemophilus influenzae.

Authors:  H Beeuwkes; V H Rutgers
Journal:  Infection       Date:  1981       Impact factor: 3.553

10.  Treatment of urinary tract infections with a combination of amoxicillin and clavulanic acid.

Authors:  A Iravani; G A Richard
Journal:  Antimicrob Agents Chemother       Date:  1982-10       Impact factor: 5.191

  10 in total
  10 in total

1.  Penetration of cefaclor into the interstitial space fluid of skeletal muscle and lung tissue in rats.

Authors:  A De La Peña; T Dalla Costa; J D Talton; E Rehak; J Gross; U Thyroff-Friesinger; A I Webb; M Müller; H Derendorf
Journal:  Pharm Res       Date:  2001-09       Impact factor: 4.200

2.  Wound infection following dog bite despite prophylactic penicillin.

Authors:  J Skurka; C Willert; R Yogev
Journal:  Infection       Date:  1986 May-Jun       Impact factor: 3.553

3.  Pharmacokinetic study of a paediatric formulation of amoxycillin and clavulanic acid in children.

Authors:  C H van Niekerk; J van den Ende; H K Hundt; E A Louw
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

4.  The role of beta-lactamase in staphylococcal resistance to penicillinase-resistant penicillins and cephalosporins.

Authors:  L K McDougal; C Thornsberry
Journal:  J Clin Microbiol       Date:  1986-05       Impact factor: 5.948

Review 5.  Amoxicillin/clavulanic acid. An update of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  P A Todd; P Benfield
Journal:  Drugs       Date:  1990-02       Impact factor: 9.546

Review 6.  Interventions for impetigo.

Authors:  Sander Koning; Renske van der Sande; Arianne P Verhagen; Lisette W A van Suijlekom-Smit; Andrew D Morris; Christopher C Butler; Marjolein Berger; Johannes C van der Wouden
Journal:  Cochrane Database Syst Rev       Date:  2012-01-18

7.  Randomized clinical trial of topical mupirocin versus oral erythromycin for impetigo.

Authors:  J Goldfarb; D Crenshaw; J O'Horo; E Lemon; J L Blumer
Journal:  Antimicrob Agents Chemother       Date:  1988-12       Impact factor: 5.191

8.  USE OF AMOXICILLIN AND CLAVULANIC ACID (AUGMENTIN) IN THE TREATMENT OF SKIN AND SOFT TISSUE INFECTIONS IN CHILDREN.

Authors:  P K Kar
Journal:  Med J Armed Forces India       Date:  2017-06-26

Review 9.  Interventions for cellulitis and erysipelas.

Authors:  Sally A Kilburn; Peter Featherstone; Bernie Higgins; Richard Brindle
Journal:  Cochrane Database Syst Rev       Date:  2010-06-16

Review 10.  Drug repurposing screens and synergistic drug-combinations for infectious diseases.

Authors:  Wei Zheng; Wei Sun; Anton Simeonov
Journal:  Br J Pharmacol       Date:  2017-07-09       Impact factor: 8.739

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.